Last updated: February 15, 2026
What is the current market landscape for Enzalutamide (NDC 51759-0204)?
Enzalutamide is an androgen receptor inhibitor used primarily in the treatment of prostate cancer. The specific NDC 51759-0204 relates to a 40 mg strength, currently marketed by pharmaceutical companies such as AstraZeneca. Its primary indication covers metastatic castration-resistant prostate cancer (mCRPC).
The drug competes in a market estimated at over $4 billion globally (IMS Health, 2022), with key competitors including apalutamide and darolutamide.
How does the patent landscape affect future market potential?
The patent for enzalutamide expired in the United States in 2024, opening the market to generic competition. AstraZeneca's exclusivity, including market protections and pediatric exclusivity, began in 2012 and is expected to end by 2024.
Lawsuits and patent challenges are anticipated to influence timing for generics' market entry, which could occur as early as late 2024 or early 2025. The presence of patents extending into 2024 affects pricing and market entry strategies.
What are the key factors driving market volume?
Global prostate cancer incidence exceeds 1.4 million new cases annually (WHO, 2021). The majority of those affected are male patients aged over 65. The expansion of combination therapies and earlier line treatments also influence the volume of enzalutamide prescriptions.
In the US alone, about 30,000 patients are treated with enzalutamide annually, reflecting a stable yet gradually increasing demand with compound annual growth rate (CAGR) estimated at 2.5% over the next five years, accounting for increased adoption and expanding indications.
How are market prices trending, and what are forecasts?
Current Price Range: Wholesale acquisition cost (WAC) for a 30-day supply of 40 mg enzalutamide ranges from $4,100 to $4,600 in the US (GoodRx, 2023).
Post-Patent Dynamics: With patent expiration, brand-name pricing is expected to decline by approximately 20-40% within the first year of generic availability, driven by market entry and competition.
Price Reductions and Generics: Once generics enter, projections estimate average patient costs could reduce by 50% or more. The price reduction will depend on manufacturer strategies, market penetration speed, and payer negotiations.
Price projections over the next five years:
| Year |
Projected Average Price (per 30-day supply) |
Key Influencing Factors |
| 2023 |
$4,300 (current) |
Limited generic presence |
| 2024 |
$3,200 - $3,800 |
Patent expiry; initial generic launches |
| 2025 |
$2,500 - $3,200 |
Increased generic competition; market stabilization |
| 2026 |
$2,000 - $2,800 |
Market saturation; price competition |
| 2027 |
$1,800 - $2,500 |
Payer negotiations; volume-based discounts |
How will market entry of generics influence pricing?
Generic competition typically reduces prices by 50% within the first year of market entry. Competition intensity and market penetration pace are critical; some formulations or formulations may face delays due to manufacturing or regulatory hurdles.
The potential entry of biosimilars or alternative therapies could further influence pricing, though currently, enzalutamide’s patent landscape is the primary determinant.
Key Takeaways
- Enzalutamide (NDC 51759-0204) faces a patent expiration in 2024, opening it to generic competition.
- Industry reports estimate 2023 retail prices at approximately $4,100–$4,600 per month.
- Post-generic entry, prices likely fall by 50% within one year; continued competition could bring further reductions.
- Market volume growth is modest, driven by increased prostate cancer diagnoses and treatment adoption.
- The primary pricing influence hinges on patent enforcement and generic market penetration speed.
5 FAQs
1. When will generic versions of enzalutamide become available?
Generic versions are likely to enter the US market in late 2024 or early 2025 following patent expiry and resolving any patent litigation.
2. How much will prices decrease once generics enter?
Prices can decrease by approximately 50% within the first year of generic entry, with additional reductions possible as competition consolidates.
3. What are the main factors influencing market growth?
Market growth hinges on increasing prostate cancer diagnoses, early adoption of enzalutamide in treatment protocols, and expansion into earlier lines of therapy.
4. How do regulatory delays impact pricing?
Delays in FDA approval or patent litigation prolong brand-name dominance, maintaining higher prices and slowing generic price reductions.
5. What are the implications for investors?
The expiration of patent rights presents an opportunity for generic manufacturers to capture market share. Innovator companies may face revenue declines, prompting strategic shifts in marketing and pipeline development.
Sources:
- IMS Health, 2022.
- GoodRx, 2023.
- World Health Organization, 2021.
